UBS cuts Medtronic stock price target on IPO dilution impact By Investing.com

UBS cut Medtronic's price target to $90 from $104 while keeping a Neutral rating, citing the earnings impact from the MMED IPO and trimming FY2027 EPS to $6.03. Medtronic also lowered FY2026 non-GAAP EPS guidance to $5.50-$5.54 from $5.62-$5.66, implying a roughly $0.04 per-share Q4 dilution from the IPO. Offset somewhat by recent FDA clearance for Stealth AXiS and the completed $585 million CathWorks acquisition, the overall tone remains cautious on near-term earnings.

Analysis

MDT looks less like a broken story and more like a “show-me” transition where near-term EPS optics are being deliberately sacrificed to de-risk the portfolio reset. The market should care that the dilution is mechanical and front-loaded, while the strategic value creation is back-end loaded; that usually creates the most attractive entry point when the stock is already near cycle lows and multiple analysts are still revising numbers downward. The key second-order effect is that management now has more room to prioritize product mix and capital allocation over headline EPS, which can improve quality of earnings over the next 4–6 quarters even if reported growth remains muted.

The biggest loser in the near term is sentiment durability: once estimates are cut, buy-side owners tend to wait for a clean stabilization print before adding risk, which can cap rebounds for several months. But that also creates a potential squeeze setup if execution surprises even modestly on procedure growth, launch adoption, or margin stability, because positioning should be light after repeated estimate resets. The spinoff/transaction framework also tends to benefit adjacent med-tech peers by reframing valuation around focused end markets, so any rerating in MDT could spill over to slower-growth large-cap healthcare names if investors decide the sector is under-owned rather than impaired.

Contrarian view: the market may be over-anchoring on the EPS cut and underestimating the optionality from a cleaner corporate structure plus incremental product/regulatory catalysts. If the new guidance floor holds, the stock does not need a heroic growth re-acceleration to rerate; it only needs evidence that the downside to earnings is finite and that the reshaped portfolio can compound modestly above low-single-digit expectations. The risk is that more integration or portfolio-transition costs emerge over the next 1–2 quarters, which would turn this from a valuation reset into a longer de-rating cycle.

Key Decisions for Investors

• Initiate a starter long MDT position over 2-3 sessions, sized small until the next quarterly update; risk/reward improves if the stock remains within 3-5% of current levels while estimates continue to wash out, but cut if another guidance reduction arrives.
• Use MDT Jan-2027 call spreads to express a recovery view with defined downside; the setup favors modest multiple expansion rather than a sharp fundamental breakout, so structured upside is better than outright equity risk.
• Pair trade: long MDT / short a more fully valued large-cap med-tech peer basket on a 3-6 month horizon; thesis is that MDT has more valuation repair potential because expectations have already been reset harder than the group.
• Avoid chasing the stock on any one-day relief rally; wait for either post-earnings stabilization or a failed low that holds near the 52-week low, since the name is still vulnerable to another round of estimate cuts over the next 1-2 quarters.
• If MDT reclaims its pre-cut valuation band without a corresponding earnings inflection, take profits quickly; the trade works best on multiple expansion from depressed sentiment, not on a structural re-rating beyond fair value.